Ligandrol - Vyxeos (Daunorubicin, Cytarabine) Interaction

Interaction Details

Daunorubicin, Cytarabine is classified as belonging to the following category: Hepatotoxic Drugs

Theoretically, concomitant use might have additive hepatotoxic effects.
In case reports, patients were diagnosed with liver injury thought to be related to the use of products containing ligandrol.

Interaction Rating

Likelihood of Occurrence

Interaction has been documented in animal or in lab research, or the interaction has been documented in humans but is limited to case reports or conflicting clinical research exists

References

• Barbara M, Dhingra S, Mindikoglu AL. Drug-induced liver injury associated with alpha bolic (RAD-140) and alpha elite (RAD-140 and LGD-4033). ACG Case Rep J 2020;7(6):e00409.
• Barbara M, Dhingra S, Mindikoglu AL. Ligandrol (LGD-4033)-Induced Liver Injury. ACG Case Rep J 2020;7(6):e00370.
• Koller T, Vrbova P, Meciarova I, et al. Liver injury associated with the use of selective androgen receptor modulators and post-cycle therapy: Two case reports and literature review. World J Clin Cases 2021;9(16):4062-4071.
• Flores JE, Chitturi S, Walker S. Drug-induced liver injury by selective androgenic receptor modulators. Hepatol Commun. 2020;4(3):450-452.

Daunorubicin, Cytarabine Overview

• Daunorubicin and cytarabine lipid complex is used to treat certain types of acute myeloid leukemia (AML; a type of cancer of the white blood cells) in adults and children 1 year of age and older. Daunorubicin is in a class of medications called anthracyclines. Cytarabine is in a class of medications called antimetabolites. Daunorubicin and cytarabine lipid complex slows or stops the growth of cancer cells in your body.

Ligandrol - More Interactions

Ligandrol interacts with 344 drugs

Interaction Rating Key

These severity listings are for informational use only. Never start, stop or otherwise change your therapy before speaking with your provider.